ARTICLE | Emerging Company Profile
Tachyon’s VC round, CIRM grant drive first-in-class oncology program to clinic
Team including Quanticel co-founders has begun Phase I testing of KDM4 program that had traveled through Celgene, BMS
March 1, 2023 1:03 PM UTC
A well-traveled epigenetic program for oncology that originated at Quanticel has finally reached the clinic in the hands of Tachyon, which is deploying a grant from CIRM and a modest venture round to develop first-in-class KDM4 inhibitor TACH101.
Tachyon Therapeutics Inc. said Wednesday that the first patient had been enrolled in a Phase I study of TACH101 to treat advanced solid tumors, with a focus on gastrointestinal cancers including microsatellite instability-high (MSI-H) colorectal cancer...
BCIQ Company Profiles
BCIQ Target Profiles